Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological study.
Identifieur interne : 002252 ( PubMed/Curation ); précédent : 002251; suivant : 002253Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological study.
Auteurs : Lynda Spelman [Australie] ; Diana Rubel [Australie] ; Dedee F. Murrell [Australie] ; Jo-Ann See [Australie] ; Daniel Hewitt [Australie] ; Peter Foley [Australie] ; Robert Salmon [Australie] ; Delphine Kerob [France] ; Thierry Pascual [France] ; Stephen Shumack [Australie] ; Pablo Fernandez-Penas [Australie]Source :
- The Australasian journal of dermatology [ 1440-0960 ] ; 2016.
Descripteurs français
- KwdFr :
- Acide amino-lévulinique (usage thérapeutique), Australie, Dermatoses du cuir chevelu (traitement médicamenteux), Dermatoses faciales (traitement médicamenteux), Facteurs temps, Humains, Kératose actinique (traitement médicamenteux), Lumière du soleil, Météorologie (), Photosensibilisants (usage thérapeutique), Photothérapie dynamique.
- MESH :
- traitement médicamenteux : Dermatoses du cuir chevelu, Dermatoses faciales, Kératose actinique.
- usage thérapeutique : Acide amino-lévulinique, Photosensibilisants.
- Australie, Facteurs temps, Humains, Lumière du soleil, Météorologie, Photothérapie dynamique.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Aminolevulinic Acid, Photosensitizing Agents.
- drug therapy : Facial Dermatoses, Keratosis, Actinic, Scalp Dermatoses.
- statistics & numerical data : Meteorology.
- Australia, Humans, Photochemotherapy, Sunlight, Time Factors.
Abstract
Solar (actinic) keratosis (AK) is an emergent concern worldwide and is associated with an increased risk of development of non-melanoma skin cancer, especially squamous cell carcinoma. Daylight-mediated photodynamic therapy (DL-PDT) using methyl aminolaevulinate cream has proved to be an effective, nearly painless, and more convenient alternative to conventional PDT for the treatment of AK. In a phase III, randomised, controlled trial performed in Australia, the mean irradiance (light intensity) received by patients during DL-PDT treatment, assessed via a spectroradiometer, was 305 W/m(2) (min. 40 to max. 585 W/m(2) ) with similar efficacy irrespective of intensity or dose. The objective of the present meteorological study was to assess the suitability of natural daylight to perform DL-PDT for the treatment of face and scalp AK during different periods of the year and different geographical locations and latitudes across Australia.
DOI: 10.1111/ajd.12295
PubMed: 25827200
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002278
Links to Exploration step
pubmed:25827200Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological study.</title><author><name sortKey="Spelman, Lynda" sort="Spelman, Lynda" uniqKey="Spelman L" first="Lynda" last="Spelman">Lynda Spelman</name><affiliation wicri:level="1"><nlm:affiliation>Specialist Connect, Woolloongabba, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Specialist Connect, Woolloongabba, Queensland</wicri:regionArea></affiliation></author><author><name sortKey="Rubel, Diana" sort="Rubel, Diana" uniqKey="Rubel D" first="Diana" last="Rubel">Diana Rubel</name><affiliation wicri:level="1"><nlm:affiliation>Woden Dermatology, Canberra, ACT, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Woden Dermatology, Canberra, ACT</wicri:regionArea></affiliation></author><author><name sortKey="Murrell, Dedee F" sort="Murrell, Dedee F" uniqKey="Murrell D" first="Dedee F" last="Murrell">Dedee F. Murrell</name><affiliation wicri:level="1"><nlm:affiliation>Sydney and University of NSW, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Sydney and University of NSW, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="See, Jo Ann" sort="See, Jo Ann" uniqKey="See J" first="Jo-Ann" last="See">Jo-Ann See</name><affiliation wicri:level="1"><nlm:affiliation>Central Sydney Dermatology, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Central Sydney Dermatology, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Hewitt, Daniel" sort="Hewitt, Daniel" uniqKey="Hewitt D" first="Daniel" last="Hewitt">Daniel Hewitt</name><affiliation wicri:level="1"><nlm:affiliation>Skin and Cancer Foundation, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Skin and Cancer Foundation, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Foley, Peter" sort="Foley, Peter" uniqKey="Foley P" first="Peter" last="Foley">Peter Foley</name><affiliation wicri:level="1"><nlm:affiliation>Skin and Cancer Foundation Inc., Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Skin and Cancer Foundation Inc., Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Salmon, Robert" sort="Salmon, Robert" uniqKey="Salmon R" first="Robert" last="Salmon">Robert Salmon</name><affiliation wicri:level="1"><nlm:affiliation>Illawarra Dermatology and Laser Clinic, Wollongong, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Illawarra Dermatology and Laser Clinic, Wollongong, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Kerob, Delphine" sort="Kerob, Delphine" uniqKey="Kerob D" first="Delphine" last="Kerob">Delphine Kerob</name><affiliation wicri:level="1"><nlm:affiliation>Galderma International, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Galderma International, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Pascual, Thierry" sort="Pascual, Thierry" uniqKey="Pascual T" first="Thierry" last="Pascual">Thierry Pascual</name><affiliation wicri:level="1"><nlm:affiliation>Galderma R&D SNC, Sophia Antipolis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Galderma R&D SNC, Sophia Antipolis</wicri:regionArea></affiliation></author><author><name sortKey="Shumack, Stephen" sort="Shumack, Stephen" uniqKey="Shumack S" first="Stephen" last="Shumack">Stephen Shumack</name><affiliation wicri:level="1"><nlm:affiliation>St George Dermatology and Skin Cancer Centre, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St George Dermatology and Skin Cancer Centre, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Fernandez Penas, Pablo" sort="Fernandez Penas, Pablo" uniqKey="Fernandez Penas P" first="Pablo" last="Fernandez-Penas">Pablo Fernandez-Penas</name><affiliation wicri:level="1"><nlm:affiliation>Westmead Clinical School, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Westmead Clinical School, Westmead Hospital, University of Sydney, Sydney, New South Wales</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:25827200</idno><idno type="pmid">25827200</idno><idno type="doi">10.1111/ajd.12295</idno><idno type="wicri:Area/PubMed/Corpus">002278</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002278</idno><idno type="wicri:Area/PubMed/Curation">002252</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002252</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological study.</title><author><name sortKey="Spelman, Lynda" sort="Spelman, Lynda" uniqKey="Spelman L" first="Lynda" last="Spelman">Lynda Spelman</name><affiliation wicri:level="1"><nlm:affiliation>Specialist Connect, Woolloongabba, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Specialist Connect, Woolloongabba, Queensland</wicri:regionArea></affiliation></author><author><name sortKey="Rubel, Diana" sort="Rubel, Diana" uniqKey="Rubel D" first="Diana" last="Rubel">Diana Rubel</name><affiliation wicri:level="1"><nlm:affiliation>Woden Dermatology, Canberra, ACT, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Woden Dermatology, Canberra, ACT</wicri:regionArea></affiliation></author><author><name sortKey="Murrell, Dedee F" sort="Murrell, Dedee F" uniqKey="Murrell D" first="Dedee F" last="Murrell">Dedee F. Murrell</name><affiliation wicri:level="1"><nlm:affiliation>Sydney and University of NSW, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Sydney and University of NSW, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="See, Jo Ann" sort="See, Jo Ann" uniqKey="See J" first="Jo-Ann" last="See">Jo-Ann See</name><affiliation wicri:level="1"><nlm:affiliation>Central Sydney Dermatology, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Central Sydney Dermatology, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Hewitt, Daniel" sort="Hewitt, Daniel" uniqKey="Hewitt D" first="Daniel" last="Hewitt">Daniel Hewitt</name><affiliation wicri:level="1"><nlm:affiliation>Skin and Cancer Foundation, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Skin and Cancer Foundation, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Foley, Peter" sort="Foley, Peter" uniqKey="Foley P" first="Peter" last="Foley">Peter Foley</name><affiliation wicri:level="1"><nlm:affiliation>Skin and Cancer Foundation Inc., Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Skin and Cancer Foundation Inc., Victoria</wicri:regionArea></affiliation></author><author><name sortKey="Salmon, Robert" sort="Salmon, Robert" uniqKey="Salmon R" first="Robert" last="Salmon">Robert Salmon</name><affiliation wicri:level="1"><nlm:affiliation>Illawarra Dermatology and Laser Clinic, Wollongong, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Illawarra Dermatology and Laser Clinic, Wollongong, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Kerob, Delphine" sort="Kerob, Delphine" uniqKey="Kerob D" first="Delphine" last="Kerob">Delphine Kerob</name><affiliation wicri:level="1"><nlm:affiliation>Galderma International, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Galderma International, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Pascual, Thierry" sort="Pascual, Thierry" uniqKey="Pascual T" first="Thierry" last="Pascual">Thierry Pascual</name><affiliation wicri:level="1"><nlm:affiliation>Galderma R&D SNC, Sophia Antipolis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Galderma R&D SNC, Sophia Antipolis</wicri:regionArea></affiliation></author><author><name sortKey="Shumack, Stephen" sort="Shumack, Stephen" uniqKey="Shumack S" first="Stephen" last="Shumack">Stephen Shumack</name><affiliation wicri:level="1"><nlm:affiliation>St George Dermatology and Skin Cancer Centre, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>St George Dermatology and Skin Cancer Centre, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Fernandez Penas, Pablo" sort="Fernandez Penas, Pablo" uniqKey="Fernandez Penas P" first="Pablo" last="Fernandez-Penas">Pablo Fernandez-Penas</name><affiliation wicri:level="1"><nlm:affiliation>Westmead Clinical School, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Westmead Clinical School, Westmead Hospital, University of Sydney, Sydney, New South Wales</wicri:regionArea></affiliation></author></analytic><series><title level="j">The Australasian journal of dermatology</title><idno type="eISSN">1440-0960</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aminolevulinic Acid (therapeutic use)</term><term>Australia</term><term>Facial Dermatoses (drug therapy)</term><term>Humans</term><term>Keratosis, Actinic (drug therapy)</term><term>Meteorology (statistics & numerical data)</term><term>Photochemotherapy</term><term>Photosensitizing Agents (therapeutic use)</term><term>Scalp Dermatoses (drug therapy)</term><term>Sunlight</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acide amino-lévulinique (usage thérapeutique)</term><term>Australie</term><term>Dermatoses du cuir chevelu (traitement médicamenteux)</term><term>Dermatoses faciales (traitement médicamenteux)</term><term>Facteurs temps</term><term>Humains</term><term>Kératose actinique (traitement médicamenteux)</term><term>Lumière du soleil</term><term>Météorologie ()</term><term>Photosensibilisants (usage thérapeutique)</term><term>Photothérapie dynamique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Aminolevulinic Acid</term><term>Photosensitizing Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Facial Dermatoses</term><term>Keratosis, Actinic</term><term>Scalp Dermatoses</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Meteorology</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Dermatoses du cuir chevelu</term><term>Dermatoses faciales</term><term>Kératose actinique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acide amino-lévulinique</term><term>Photosensibilisants</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Australia</term><term>Humans</term><term>Photochemotherapy</term><term>Sunlight</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Australie</term><term>Facteurs temps</term><term>Humains</term><term>Lumière du soleil</term><term>Météorologie</term><term>Photothérapie dynamique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Solar (actinic) keratosis (AK) is an emergent concern worldwide and is associated with an increased risk of development of non-melanoma skin cancer, especially squamous cell carcinoma. Daylight-mediated photodynamic therapy (DL-PDT) using methyl aminolaevulinate cream has proved to be an effective, nearly painless, and more convenient alternative to conventional PDT for the treatment of AK. In a phase III, randomised, controlled trial performed in Australia, the mean irradiance (light intensity) received by patients during DL-PDT treatment, assessed via a spectroradiometer, was 305 W/m(2) (min. 40 to max. 585 W/m(2) ) with similar efficacy irrespective of intensity or dose. The objective of the present meteorological study was to assess the suitability of natural daylight to perform DL-PDT for the treatment of face and scalp AK during different periods of the year and different geographical locations and latitudes across Australia.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25827200</PMID><DateCreated><Year>2016</Year><Month>01</Month><Day>29</Day></DateCreated><DateCompleted><Year>2017</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-0960</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Australasian journal of dermatology</Title><ISOAbbreviation>Australas. J. Dermatol.</ISOAbbreviation></Journal><ArticleTitle>Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological study.</ArticleTitle><Pagination><MedlinePgn>24-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ajd.12295</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">Solar (actinic) keratosis (AK) is an emergent concern worldwide and is associated with an increased risk of development of non-melanoma skin cancer, especially squamous cell carcinoma. Daylight-mediated photodynamic therapy (DL-PDT) using methyl aminolaevulinate cream has proved to be an effective, nearly painless, and more convenient alternative to conventional PDT for the treatment of AK. In a phase III, randomised, controlled trial performed in Australia, the mean irradiance (light intensity) received by patients during DL-PDT treatment, assessed via a spectroradiometer, was 305 W/m(2) (min. 40 to max. 585 W/m(2) ) with similar efficacy irrespective of intensity or dose. The objective of the present meteorological study was to assess the suitability of natural daylight to perform DL-PDT for the treatment of face and scalp AK during different periods of the year and different geographical locations and latitudes across Australia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To determine daylight irradiance during a complete year in eight different geographical locations throughout Australia, we used meteorological software (Meteonorm, Meteotest, Bern, Switzerland), and available solar radiation and weather data from 1986-2005.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The average daily irradiance remained within the levels (40-585 W/m(2) ) measured during the clinical DL-PDT study in Australia, throughout the year and in all geographical locations investigated (yearly average from Darwin 548 W/m(2) to Hobart 366 W/m(2) ).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">DL-PDT for the treatment of face and scalp AK in Australia can be performed effectively throughout the entire year as long as weather conditions permit daylight exposure and allow participants to remain under direct light for 2 h.</AbstractText><CopyrightInformation>© 2015 The Australasian College of Dermatologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spelman</LastName><ForeName>Lynda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Specialist Connect, Woolloongabba, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Probity Medical Research Inc., Waterloo, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubel</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Woden Dermatology, Canberra, ACT, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Probity Medical Research Inc., Waterloo, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murrell</LastName><ForeName>Dedee F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Sydney and University of NSW, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>See</LastName><ForeName>Jo-Ann</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Central Sydney Dermatology, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hewitt</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Skin and Cancer Foundation, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foley</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Skin and Cancer Foundation Inc., Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St Vincent's Hospital, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Probity Medical Research Inc., Waterloo, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Illawarra Dermatology and Laser Clinic, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerob</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Galderma International, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascual</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Galderma R&D SNC, Sophia Antipolis, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shumack</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>St George Dermatology and Skin Cancer Centre, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Probity Medical Research Inc., Waterloo, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Penas</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-4882-1564</Identifier><AffiliationInfo><Affiliation>Westmead Clinical School, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Australas J Dermatol</MedlineTA><NlmUniqueID>0135232</NlmUniqueID><ISSNLinking>0004-8380</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>88755TAZ87</RegistryNumber><NameOfSubstance UI="D000622">Aminolevulinic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000622" MajorTopicYN="N">Aminolevulinic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005148" MajorTopicYN="N">Facial Dermatoses</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055623" MajorTopicYN="N">Keratosis, Actinic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055904" MajorTopicYN="N">Meteorology</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010778" MajorTopicYN="Y">Photochemotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012536" MajorTopicYN="N">Scalp Dermatoses</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013472" MajorTopicYN="Y">Sunlight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Australia</Keyword><Keyword MajorTopicYN="N">daylight irradiance</Keyword><Keyword MajorTopicYN="N">daylight-mediated photodynamic therapy</Keyword><Keyword MajorTopicYN="N">meteorological study</Keyword><Keyword MajorTopicYN="N">methyl aminolaevulinate</Keyword><Keyword MajorTopicYN="N">solar (actinic) keratosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>06</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25827200</ArticleId><ArticleId IdType="doi">10.1111/ajd.12295</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002252 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002252 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25827200
|texte= Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25827200" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |